Prospect Of Biosimilar-To-Biosimilar Switching Spurs Call For Postmarketing Data

 
• By Sue Sutter
  
Rail switches in yard off mainline
The potential for patients to be switched back and forth between biosimilars has innovators calling for FDA action.

More from Biosimilars

More from Biosimilars & Generics